CGRP Forum is made possible thanks to support from AbbVie, Lilly, Organon and Pfizer, all of whom have no influence or control of editorial content. More information is available here »
A change in reimbursement policy in Germany allowing earlier use of CGRP mAbs in patients with at least four migraine days per month has led to more treatment responders in clinical practice.1 Results of a retrospective cohort study of CGRP-mAb naïve patients with episodic or chronic migraine, showed a higher ≥ 50% responder rate in …
Read more »Promising real-life data have been reported with erenumab in patients with highly refractory migraine. Those with episodic migraine (EM) had tried at least five approved preventive medications and those with chronic migraine (CM) had tried at least six. Reasons for stopping previous therapies were lack of efficacy, adverse effects, or contraindications. Data collected on 100 …
Read more »At least 7/10 patients with episodic or chronic migraine treated with erenumab achieved beneficial effects, according to preliminary real world data from 70 participating centres in the TELESCOPE study, an online survey carried out from July to December 2019. Data from 10-20 consecutive patients per centre showed there was an average reduction of eight migraine …
Read more »
This program is funded in part via an independent educational grant from AbbVie.
Organon has provided sponsorship towards this independent resource. Organon has had no editorial input or control over content, nor opportunity to influence.
Financial support was provided as GMG Knowledge Gap Grant from Pfizer Inc, Pfizer have provided only financial support and had no input into the content provided.
